ROCHE HOLDINGS AG (RHHBY)

34.70
0.14 0.41
OTC
Prev Close 34.56
Open 34.74
Day Low/High 34.66 / 34.85
52 Wk Low/High 25.10 / 35.90
Volume 1.65M
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)

Latest News

Genentech's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Advanced Bladder Cancer

Genentech's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS).

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

Genentech Presents A Broad Range Of Data For Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits For People With Hemophilia A At The ISTH 2019 Congress

Genentech Presents A Broad Range Of Data For Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits For People With Hemophilia A At The ISTH 2019 Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data for Hemlibra ® (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII inhibitors at the International Society...

Genentech Announces Positive Results For First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) In Children With The Flu

Genentech Announces Positive Results For First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) In Children With The Flu

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that XOFLUZA™ (baloxavir marboxil) was well-tolerated in children with the flu.

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

Phase III PEMPHIX Study Showed That Genentech's Rituxan (Rituximab) Is Superior To Standard Of Care In Achieving Sustained Remission In Patients With Pemphigus Vulgaris

Phase III PEMPHIX Study Showed That Genentech's Rituxan (Rituximab) Is Superior To Standard Of Care In Achieving Sustained Remission In Patients With Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan ® (rituximab) compared to mycophenolate mofetil...

FDA Grants Priority Review To Genentech's Rituxan (Rituximab) In Children With Two Rare Blood Vessel Disorders

FDA Grants Priority Review To Genentech's Rituxan (Rituximab) In Children With Two Rare Blood Vessel Disorders

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's Gazyva (Obinutuzumab) Delivers Positive Topline Results For Phase II Lupus Nephritis Study

Genentech's Gazyva (Obinutuzumab) Delivers Positive Topline Results For Phase II Lupus Nephritis Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva ® (obinutuzumab) for adults with proliferative lupus...

FDA Grants Genentech's Polivy Accelerated Approval For People With Previously Treated Aggressive Lymphoma

FDA Grants Genentech's Polivy Accelerated Approval For People With Previously Treated Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Spark Therapeutics' Shares Fall on Roche Acquisition Delay

Spark Therapeutics' Shares Fall on Roche Acquisition Delay

Shares of Spark Therapeutics slide amid a second regulatory-related delay of its $4.3 billion deal with Swiss pharmaceuticals group Roche Holdings AG.

Not There Yet

Despite the S&P 500’s rally off Monday’s low, my Oscillator shows we won’t be overbought for another week or so.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Phase III Study Showed XOFLUZA (Baloxavir Marboxil) Is Effective At Preventing Influenza Infection

Phase III Study Showed XOFLUZA (Baloxavir Marboxil) Is Effective At Preventing Influenza Infection

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III BLOCKSTONE study, conducted by Shionogi & Co.

Xolair (Omalizumab) Significantly Reduced Nasal Polyps And Congestion Symptoms In Adults With Chronic Rhinosinusitis With Nasal Polyps In Two Phase III Studies

Xolair (Omalizumab) Significantly Reduced Nasal Polyps And Congestion Symptoms In Adults With Chronic Rhinosinusitis With Nasal Polyps In Two Phase III Studies

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline data from two Phase III multicenter studies evaluating Xolair ® (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps...

Roche Launches First In Vitro Diagnostic IHC Test To Detect ROS1 Protein In Cancers

Roche Launches First In Vitro Diagnostic IHC Test To Detect ROS1 Protein In Cancers

- Roche's VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market

Roche Receives FDA Clearance To Expand Testing Menu On Cobas 6800/8800 Systems For Sexually Transmitted Diseases

Roche Receives FDA Clearance To Expand Testing Menu On Cobas 6800/8800 Systems For Sexually Transmitted Diseases

- The addition of the cobas TV/MG test to the testing menu provides the flexibility to process up to four sexually transmitted infections from one patient sample

Genentech's Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, ROS1 Or ALK Gene Fusions In Children And Adolescents

Genentech's Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, ROS1 Or ALK Gene Fusions In Children And Adolescents

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adolescents with recurrent or refractory solid...

Genentech Announces FDA Approval For Venclexta Plus Gazyva For People With Previously Untreated Chronic Lymphocytic Leukemia

Genentech Announces FDA Approval For Venclexta Plus Gazyva For People With Previously Untreated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech To Present New Data Highlighting Comprehensive Approach To Cancer Care At 2019 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech To Present New Data Highlighting Comprehensive Approach To Cancer Care At 2019 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 17 approved and investigational medicines across 27 cancer types, including hard-to-treat and rare tumors, will be presented at the...

Genentech To Present New OCREVUS (Ocrelizumab) Data Analyses Showing Significant Reduction Of Disability Progression In Relapsing And Primary Progressive Multiple Sclerosis At The AAN Annual Meeting

Genentech To Present New OCREVUS (Ocrelizumab) Data Analyses Showing Significant Reduction Of Disability Progression In Relapsing And Primary Progressive Multiple Sclerosis At The AAN Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new OCREVUS ® (ocrelizumab) data in relapsing and primary progressive multiple sclerosis (MS) were presented at the 71st American Academy of Neurology (AAN) Annual...

Genentech Presents Data From The Risdiplam Pivotal FIREFISH And SUNFISH Studies In Spinal Muscular Atrophy At The 2019 AAN Annual Meeting

Genentech Presents Data From The Risdiplam Pivotal FIREFISH And SUNFISH Studies In Spinal Muscular Atrophy At The 2019 AAN Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data from the dose-finding Part 1 of the pivotal FIREFISH trial showing infants with Type 1 spinal muscular atrophy (SMA) achieved key motor milestones after one year...

Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For MRNA ISH Tissue Analysis

Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For MRNA ISH Tissue Analysis

New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform

FDA Approves Genentech's Kadcyla For Adjuvant Treatment Of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

FDA Approves Genentech's Kadcyla For Adjuvant Treatment Of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Nimble Therapeutics Spins Out From Roche To Commercialize Novel Drug Discovery Technology With Financing From Telegraph Hill Partners

Nimble Therapeutics Spins Out From Roche To Commercialize Novel Drug Discovery Technology With Financing From Telegraph Hill Partners

MADISON, Wis., April 30, 2019 /PRNewswire/ -- Nimble Therapeutics has begun operating as a standalone business after spinning out from F.

New Genentech Data At The 2019 AAN Annual Meeting Showcase Breadth And Promise Of Neuroscience Portfolio

New Genentech Data At The 2019 AAN Annual Meeting Showcase Breadth And Promise Of Neuroscience Portfolio

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines for the treatment of neurological conditions will be presented at the 71st American Academy of Neurology...

FDA Approves Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Adults With Extensive-Stage Small Cell Lung Cancer

FDA Approves Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Adults With Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Genentech's Tecentriq In Combination With Abraxane Accelerated Approval For People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

FDA Grants Genentech's Tecentriq In Combination With Abraxane Accelerated Approval For People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

Genentech Submits Supplemental New Drug Application To FDA For Venclexta Plus Gazyva For Previously Untreated Chronic Lymphocytic Leukemia With Co-Existing Medical Conditions

Genentech Submits Supplemental New Drug Application To FDA For Venclexta Plus Gazyva For Previously Untreated Chronic Lymphocytic Leukemia With Co-Existing Medical Conditions

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the submission of a supplemental New Drug Application to the U.